Crohn’s Disease and Ulcerative Colitis

Crohn’s disease and ulcerative colitis are the two primary forms of inflammatory bowel disease (IBD), affecting over 4.1 million American adults in 2026. While both conditions involve chronic inflammation of the digestive tract triggered by autoimmune responses, they differ significantly in location, severity patterns, and treatment approaches. Understanding these distinctions empowers patients to pursue targeted therapies from conventional medications to emerging integrative solutions combining natural TNF-α blockers with lifestyle modifications that address root inflammatory pathways.

Quick Answer: How Crohn’s Disease and Ulcerative Colitis Diverge

Both conditions fall under the inflammatory bowel disease umbrella, but they attack the digestive system differently. Ulcerative colitis confines its damage to the colon and rectum, affecting only the innermost lining of the intestinal wall. Crohn’s disease shows no such restraint it can inflame any segment from mouth to anus and penetrates deeper tissue layers.

According to Medicaldaily, recent data translates to an estimated 4.1 million American adults with IBD, with ulcerative colitis affecting about 3.1 million and Crohn’s disease affecting about 1.3 million. This prevalence gap matters because treatment protocols differ based on disease location and depth of tissue involvement.

@keyframes hoox-lf-in-hoox-f-3fab2e50-5b3d-440f-a831-85be67-top {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-3fab2e50-5b3d-440f-a831-85be67-top 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-top .hoox-disabled-text a:hover {
text-decoration: none;
}

Patients often confuse symptoms between the two, leading to delayed diagnosis. Rectal bleeding appears more frequently with ulcerative colitis, while Crohn’s patients typically experience abdominal pain and weight loss as dominant early signs. Both conditions share overlapping symptoms: chronic diarrhea, fatigue, and unpredictable flare cycles that disrupt daily functioning.

Characteristic	Ulcerative Colitis	Crohn’s Disease
Location	Colon and rectum only	Anywhere from mouth to anus
Inflammation Depth	Mucosal lining only	Full thickness of bowel wall
Pattern	Continuous inflammation	Patchy “skip lesions”
Rectal Bleeding	Very common	Less common
Abdominal Pain	Lower left quadrant	Lower right or diffuse
Complications	Toxic megacolon, colon cancer risk	Fistulas, strictures, abscesses

Understanding your specific diagnosis shapes treatment expectations. Many patients explore common IBD questions when first diagnosed, seeking clarity on prognosis and management options.

Why Your Immune System Attacks the Digestive Tract [Autoimmune Mechanisms]

Inflammatory bowel disease operates through a case of mistaken identity. Your immune system, designed to protect against foreign invaders, begins targeting your own intestinal tissue as if it were an infection. This autoimmune misrecognition triggers a cascade of inflammatory responses that damage the gut lining.

The central player in this process is a protein called tumor necrosis factor alpha (TNF-α). Under normal circumstances, TNF-α helps fight actual infections. In IBD patients, the body produces excessive amounts, creating sustained inflammation that refuses to switch off. White blood cells infiltrate the intestinal walls, releasing chemicals that cause swelling, ulceration, and tissue death.

Genetic predisposition plays a role, but environmental factors often trigger the initial flare. These include antibiotic use that disrupts gut flora, smoking (which doubles Crohn’s risk), stress, and certain dietary patterns. The interaction between genes and environment creates a perfect storm where the immune system loses tolerance to beneficial gut bacteria.

According to the Nih, recent statistics and insights about Crohn’s disease and ulcerative colitis show prevalence rates continuing to climb across industrialized nations. The hygiene hypothesis suggests that reduced microbial exposure in childhood may leave immune systems more prone to overreacting later in life.

Once the inflammatory cycle begins, it tends to self-perpetuate. Damaged intestinal lining allows bacteria to penetrate deeper layers, provoking stronger immune responses. Breaking this cycle requires interventions that calm the immune system while healing damaged tissue. Patients increasingly seek understanding our integrative approach to address both mechanisms simultaneously.

The Five-Stage Severity Framework IBD Specialists Use in 2026

Not all IBD cases warrant the same treatment intensity. Gastroenterologists classify disease severity using a five-stage framework that guides therapeutic decisions. Understanding where you fall on this spectrum helps set realistic expectations and avoid under-treatment.

• Stage One – Low Severity: Fewer than four bowel movements daily, minimal bleeding, no weight loss, normal energy levels, inflammation confined to limited colon segments.
• Stage Two – Low-Medium Severity: Four to six bowel movements daily, intermittent rectal bleeding, mild fatigue, some abdominal discomfort, inflammation spreading but still localized.
• Stage Three – Medium Severity: Six to eight bowel movements daily, regular bleeding, noticeable weight loss, moderate pain affecting daily activities, anemia developing.
• Stage Four – Medium-High Severity: Eight to ten bowel movements daily, significant bleeding requiring transfusion consideration, substantial weight loss, severe pain, extraintestinal symptoms appearing.
• Stage Five – High Severity: More than ten bowel movements daily, continuous bleeding, dangerous weight loss, debilitating pain, risk of toxic megacolon or perforation, hospitalization often required.

Higher stages demand more aggressive intervention. Patients at stages four and five face the steepest climb to remission. Conventional medications alone sometimes prove insufficient at these levels, prompting exploration of targeted IBD solutions that address stubborn inflammation through complementary pathways.

When Conventional Medications Fail: The Remission Gap Problem

Standard IBD treatment follows a step-up approach: anti-inflammatory drugs like mesalamine, then corticosteroids for flares, followed by immunomodulators, and finally biologics if needed. This progression works adequately for many patients. However, a significant portion experiences treatment resistance or loses response over time.

Up to 40% of patients on anti-TNF biologics eventually develop antibodies that neutralize the medication. Others tolerate biologics poorly, facing infections or infusion reactions that make continuation impossible. Others achieve partial response symptoms improve but never fully resolve. They enter a gray zone where disease activity persists at a lower intensity.

This remission gap proves deeply frustrating. Patients follow medical advice, take medications as prescribed, yet still cannot trust their digestion. They plan outings around bathroom access, decline social invitations, and modify work arrangements around unpredictable symptoms. Quality of life suffers despite being “in treatment.”

Diminished expectations become normal. Patients start accepting功能障碍-level symptoms as their baseline when true remission remains possible. Reading real patient remission experiences can shift this perspective, demonstrating that better outcomes exist even after conventional approaches fall short.

How Natural TNF-α Blockers Target Colon Inflammation Pathways

Natural TNF-α inhibitors function through mechanisms parallel to pharmaceutical biologics, but with different molecular structures. Certain botanical compounds demonstrate the ability to bind TNF-α receptors or reduce TNF-α production, dampening the inflammatory cascade without suppressing the entire immune system.

Traditional Chinese Medicine has documented anti-inflammatory herbs for centuries. Modern research now validates specific botanicals for their TNF-α modulating properties. These compounds work through multiple pathways: reducing pro-inflammatory cytokine production, inhibiting nuclear factor kappa B (NF-κB) activation, and promoting mucosal healing.

Unlike single-molecule drugs, herbal formulations contain dozens of bioactive compounds that address inflammation through complementary mechanisms. This multi-target approach may explain why some patients respond to natural formulations after failing pharmaceutical options. The broader activity spectrum hits pathways that single drugs miss.

The four-herb formulation combines botanicals selected specifically for colon inflammation. Each herb contributes distinct anti-inflammatory actions while supporting overall digestive function. Together, they create synergistic effects greater than any single ingredient would produce alone.

Building Your Remission Protocol: Medication + Integrative Strategies

Achieving lasting remission rarely comes from a single intervention. The most successful approach combines conventional medical treatment with integrative strategies that address inflammation from multiple angles. Think of it as building layers of protection rather than relying on one defensive wall.

• Dietary Modification: Identify and eliminate personal trigger foods through systematic elimination protocols. Common culprits include dairy, gluten, high-fiber raw vegetables during flares, and processed foods with emulsifiers.
• Stress Management: Practice vagus nerve stimulation techniques like slow breathing, meditation, or gentle yoga. Stress directly activates inflammatory pathways through the gut-brain axis.
• Sleep Optimization: Aim for seven to nine hours of quality sleep. Sleep deprivation increases inflammatory markers and impairs immune regulation.
• Microbiome Support: Use evidence-based probiotic strains during antibiotic recovery. Consider prebiotic foods when inflammation allows to feed beneficial bacteria.
• Anti-Inflammatory Supplementation: Add natural TNF-α modulators from botanical sources to complement pharmaceutical interventions.
• Regular Monitoring: Track symptoms objectively using validated indexes. Partner with gastroenterologists who monitor fecal calprotectin and inflammatory markers regularly.

The goal extends beyond symptom suppression. True remission means mucosal healing actual tissue repair visible on colonoscopy. This deeper healing reduces long-term complication risks and improves quality of life. Patients ready to explore integrative options often find that adding natural anti-inflammatory support accelerates their progress toward this goal.

Key Takeaways: Living Beyond the Bathroom

Inflammatory bowel disease imposes heavy burdens, but remission remains achievable for most patients with comprehensive treatment approaches. The path may require combining conventional medications with integrative strategies that conventional gastroenterology alone does not typically address.

Aspect	Active Disease State	Remission State
Daily Bathroom Trips	8-15+ urgent visits	2-4 normal movements
Sleep Quality	Interrupted frequently	Uninterrupted rest
Work/School Attendance	Often compromised	Regular participation
Social Activities	Limited by bathroom access anxiety	Full engagement possible
Dietary Freedom	Severely restricted	Expanded with exceptions for specific triggers
Energy Level	Depleted, unpredictable	Consistent,恢复正常

Moving from active disease to remission transforms daily existence. Patients regain control over their schedules, relationships, and professional ambitions. The digestive system ceases dictating life choices. Access to comprehensive digestive wellness resources provides ongoing support through the remission journey.

FAQ: Crohn’s Disease and Ulcerative Colitis

Can natural supplements actually help when medications haven’t worked?

Yes, for many patients. Natural TNF-α blockers work through different pathways than pharmaceutical biologics, offering alternative routes to inflammation control. Multi-herb formulations provide broader anti-inflammatory activity than single-molecule drugs. Patients who developed antibody resistance to biologics may respond to botanical compounds with different molecular structures.

How long before noticing improvement with integrative IBD approaches?

Typically four to eight weeks. Natural anti-inflammatory botanicals require time to modulate immune function and promote mucosal healing. Unlike corticosteroids that suppress symptoms rapidly, herbal TNF-α modulators work gradually to correct underlying dysfunction. Some patients report subtle improvements within two weeks, with significant symptom reduction by the two-month mark.

Is ulcerative colitis easier to treat than Crohn’s disease?

Generally, yes for colon-limited disease. Ulcerative colitis affects only the colon and superficial tissue layers, making localized treatment more feasible. Crohn’s disease penetrates deeper tissue and can involve multiple digestive tract segments, complicating therapeutic approaches. However, both conditions require comprehensive management for optimal outcomes.

Do I need to stop my current medications to try natural approaches?

No integrative means combined, not replacement. The safest approach adds natural anti-inflammatory support alongside existing medical treatment. Once significant improvement occurs, patients can discuss medication adjustment with their gastroenterologists. Never discontinue prescribed IBD medications without medical supervision, as abrupt changes risk severe flares.

What’s the difference between remission and a cure?

Remission means disease control, not elimination. IBD currently has no cure the underlying immune dysfunction persists. Remission signifies that inflammation has subsided, symptoms have resolved, and mucosal healing has occurred. Maintenance strategies remain necessary to prevent future flares, but remission allows normal daily functioning.

@keyframes hoox-lf-in-hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-3fab2e50-5b3d-440f-a831-85be67-bottom .hoox-disabled-text a:hover {
text-decoration: none;
}